Bioequivalence study of Vastofar® 40 (Atorvastatin 40 mg) film coated caplet produced by PT IFARS Pharmaceutical Laboratories in comparison with Lipitor® (Atorvastatin 40 mg) film coated tablet manufactured by Pfizer Pharmaceuticals LLC, Vega Baja, Puerto Rico, USA, imported by PT Pfizer Indonesia

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
PT Omega Medika Farma Laboratori
No Registry
INA-K0M1AAA
Tanggal Input Registry : 24-11-2023

11-10-2023
AUCt and Cmax
AUCinf, Tmax, and Half-life
 
Bioequivalence study of Vastofar® 40 (Atorvastatin 40 mg) film coated caplet produced by PT IFARS Pharmaceutical Laboratories in comparison with Lipitor® (Atorvastatin 40 mg) film coated tablet manufactured by Pfizer Pharmaceuticals LLC, Vega Baja, Puerto Rico, USA, imported by PT Pfizer Indonesia
Bioequivalence study of Vastofar® 40 (Atorvastatin 40 mg) film coated caplet produced by PT IFARS Pharmaceutical Laboratories in comparison with Lipitor® (Atorvastatin 40 mg) film coated tablet manufactured by Pfizer Pharmaceuticals LLC, Vega Baja, Puerto Rico, USA, imported by PT Pfizer Indonesia.
Interventional
The reference drug was Lipitor® (Atorvastatin 40 mg) film coated tablet manufactured by Pfizer Pharmaceuticals LLC, Vega Baja, Puerto Rico, USA, imported by PT Pfizer Indonesia. The test drug was Vastofar® 40 (Atorvastatin 40 mg) film coated caplet produced by PT IFARS Pharmaceutical Laboratories. In the morning of the sampling as scheduled, subjects were given one dose of Atotvastatin products of either formulation (reference or test), as per randomization scheme with 240 mL of water in sitting position
26
 

Inclusion Criteria:

- Willing to sign the informed consent, - Age 18 – 55 years, - Body mass index between 18 – 25 kg/m2, - Normotensive (systolic blood pressure 100 – 120 mmHg, diastolic blood pressure 60-80 mmHg), heart rate 60 – 90 beats per minute, - Healthy male (healthy criteria is determined by normal values or if outside the normal range of values but no clinically significant effects based on doctors' justification on the result of laboratory test include routine hematology, liver function, renal function, blood sugar and urinalysis; history of disease, and physical examination).

Exclusion Criteria:

- Contraindicated and/or has history of hypersensitivity to Atorvastatin or related drug, - With history or present medical condition which might significantly influence the pharmacokinetics of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease - Non-Healthy male (non-healthy criteria is determined by abnormal values or if outside the normal range of value and clinically significant effects based on doctors' justification on the result of laboratory test include routine hematology, liver function, renal function, blood sugar and urinalysis; history of disease, and physical examination), - Show abnormal result or not within acceptable range (clinically significant effect based on doctor’s justification) in the electrocardiography (ECG) test result, - Using any medication (prescription or non-prescription drug, food supplement, herbal medicine) within 7 days prior to the dosing day, - Participated in any clinical study within 3 months prior the study, - Donated or lost 300 mL (or more) of blood within 3 months prior the study, - Smoke more than 9 sticks of cigarettes a day, - Have any bleeding or coagulation disorder, - With the history of alcohol and drug abuse, - Indicate the positive result on test for HbsAg, Anti-HCV and anti-HIV, - If the study is conducted in Covid-19 pandemic situation, the exclusions criteria below must be applied: a. With history of direct contact with a Covid-19 positive person within last 14 days, b. With history or present sore throat, fever (temperature more than 37oC) or short of breath within last 14 days, c. Positive to Covid-19 antigen rapid test.
 
KET-1150/UN2.F1/ETIK/PPM.00.02/2023
Not applicable
PPUK/PPUB number
apt. Noviyanto, S.Farm